BioNTech (BNTX) and Bristol Myers Squibb Company (BM) announced the first interim data from a global randomized Phase 2 trial evaluating pumitamig, an investigational bispecific antibody targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback